{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002612","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.193375+00:00","generated_at":"2026-06-19T15:54:31.113277+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Outset Medical Q4 revenue $32M (+14% YoY); COO Vazquez retiring Apr 3","bullets":["Q4 revenue $32.0M (+14% YoY); full-year revenue $115.4M (+12.4% YoY).","GAAP gross margin 16.5% (17.1% non-GAAP); operating loss $45.1M.","Tablo installed base grew 54% YoY to ~4,000 systems; 800 home units.","FY 2023 guidance reaffirmed: revenue $140-150M, non-GAAP gross margin ~20%.","COO Martin Vazquez retiring Apr 3, 2023; expected 6-month consulting arrangement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002612","json":"https://secwatch.observer/filing/0000950170-23-002612.json","markdown":"https://secwatch.observer/filing/0000950170-23-002612.md","text":"https://secwatch.observer/filing/0000950170-23-002612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023002612/0000950170-23-002612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023002612/om-20230213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T15:54:31.113277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1fe864ac21003df86249b8aca876ffed98e9eeb","claim":"Outset Medical, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue Revenue for the fourth quarter of 2022 was $32.0 million, net income Net loss was ($41.4) million. Guidance reaffirmed.","evidence_excerpt":"Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023002612/0000950170-23-002612-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"Revenue for the fourth quarter of 2022 was $32.0 million"},{"label":"Net income","value":"Net loss was ($41.4) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f5251107b3","claim":"Martin Vazquez departed as Chief Operating Officer at Outset Medical, Inc..","evidence_excerpt":"On February 13, 2023, Martin Vazquez informed the Company of his decision to retire from his role as Chief Operating Officer of the Company effective April 3, 2023 to pursue personal opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023002612/0000950170-23-002612-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}